Medication safety principles and practice in CKD

Clinical Journal of the American Society of Nephrology

Volumn 13, Issue 11, 2018, Pages 1738-1746

  Whittaker, Chanel F ^a   Miklich, Margaret A ^b   Patel, Roshni S ^c   Fink, Jeffrey C ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^c Jefferson School of Pharmacy   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; AMINOGLYCOSIDE; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DEXTRAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLYCYRRHIZA GLABRA ROOT; HEPARIN; LINAGLIPTIN; LITHIUM; LOOP DIURETIC AGENT; METFORMIN; PETHIDINE; PHENYTOIN; PHOSPHATE BINDING AGENT; POTASSIUM SPARING DIURETIC AGENT; RENIN INHIBITOR; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; TACROLIMUS; THIAZIDE DIURETIC AGENT; THIAZOLE DERIVATIVE; UNINDEXED DRUG; ANGIOTENSIN RECEPTOR ANTAGONIST;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ANEMIA; ANTICOAGULATION; BLOOD PRESSURE REGULATION; BLOOD TRANSFUSION; BONE DISEASE; CALCIUM BALANCE; CALCIUM HOMEOSTASIS; CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DIGITALIS INTOXICATION; DISEASE EXACERBATION; DIURESIS; DRUG DOSE; DRUG SAFETY; ELECTROLYTE DISTURBANCE; GINKGO BILOBA; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; GLYCEMIC CONTROL; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPERURICEMIA; HYPOCHLOREMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; IRON OVERLOAD; IRON THERAPY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LACTIC ACIDOSIS; MEDICAL CARE; MEDICATION THERAPY MANAGEMENT; METABOLIC ALKALOSIS; MORBIDITY; MORTALITY; NATRIURESIS; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OTOTOXICITY; QUALITY OF LIFE; REVIEW; VENOUS THROMBOEMBOLISM; WATER RETENTION; COMPLICATION; HUMAN; KIDNEY TRANSPLANTATION; PATHOPHYSIOLOGY; PATIENT SAFETY;

ACUTE KIDNEY INJURY; ANEMIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER; DIURETICS; HUMANS; HYPERKALEMIA; HYPOGLYCEMIC AGENTS; HYPOKALEMIA; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MEDICATION RECONCILIATION; PATIENT SAFETY; RENAL INSUFFICIENCY, CHRONIC;

EID: 85054559361     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00580118     Document Type: Review

References (85)

1. Henrich WL, Anderson RJ: Drug use in renal failure. PostgradMed 64: 153-163, 1978
2. Reed WE Jr, Sabatini S: The use of drugs in renal failure. Semin Nephrol 6: 259-295, 1986
3. Stevens LA, Fares G, Fleming J, Martin D, Murthy K, Qiu J, Stark PC, Uhlig K, Van Lente F, Levey AS: Lowrates of testing and diagnostic codesusage ina commercial clinical laboratory: Evidence for lack of physician awareness of chronic kidney disease. J Am Soc Nephrol 16: 2439-2448, 2005
4. Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA, Hostetter TH:Chronic kidneydisease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 16: 180-188, 2005
5. Chertow GM, Lee J, Kuperman GJ, Burdick E, Horsky J, Seger DL, Lee R, Mekala A, Song J, Komaroff AL, Bates DW: Guided medication dosing for inpatients with renal insufficiency. JAMA 286: 2839-2844, 2001
6. Corsonello A, Pranno L, Garasto S, Fabietti P, Bustacchini S, Lattanzio F: Potentially inappropriate medication in elderly hospitalized patients. Drugs Aging 26[Suppl 1]: 31-39, 2009
7. Blix HS, Viktil KK, Moger TA, Reikvam A: Use of renal risk drugs in hospitalized patients with impaired renal function-an underestimated problem? NephrolDial Transplant 21: 3164-3171, 2006
8. Brown C: Prescribing principles for patients with chronic kidney disease. Pharm Pract (Granada) 18: 23-24, 2008
9. Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P: Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80: 1122-1137, 2011
10. Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, Townsend R, Okparavero A, Zhang YL, Schmid CH, Levey AS; Chronic Kidney Disease Epidemiology Collaboration: Comparisonofdrugdosing recommendations basedonmeasured GFR and kidney function estimating equations. Am J Kidney Dis 54: 33-42, 2009
11. Kappel J, Calissi P: Nephrology: 3. Safe drug prescribing for patients with renal insufficiency. CMAJ 166: 473-477, 2002
12. Nolin TD: Altered nonrenal drug clearance in ESRD. Curr Opin Nephrol Hypertens 17: 555-559, 2008
13. Brater DC: Diuretic therapy. N Engl J Med 339: 387-395, 1998
14. Wilcox CS: Metabolic and adverse effects of diuretics. Semin Nephrol 19: 557-568, 1999
15. Palmer BF: Metabolic complications associated with use of diuretics. Semin Nephrol 31: 542-552, 2011
16. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS; Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association: Renal considerations in angiotensin converting enzyme inhibitor therapy: A statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104: 1985-1991, 2001
17. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW: Efficacy and safety of benazepril for advanced chronic renal insufficiency.NEngl JMed 354: 131-140, 2006
18. Tomlinson LA, Holt SG, Leslie AR, Rajkumar C: Prevalence of ambulatory hypotension in elderly patients withCKDstages 3and 4. Nephrol Dial Transplant 24: 3751-3755, 2009
19. Toto RD, Mitchell HC, Lee HC, Milam C, Pettinger WA: Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 115: 513-519, 1991
20. Packer M, Lee WH, Medina N, Yushak M, Kessler PD: Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 106: 346-354, 1987
21. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S: Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: Nested case-control study. BMJ 346: e8525, 2013
22. Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ: Acute kidney injury from SGLT2 inhibitors: Potential mechanisms. Nat Rev Nephrol 12: 711-712, 2016
23. Palevsky PM, Zhang JH, Seliger SL, Emanuele N, Fried LF; VA NEPHRON-D Study: Incidence, severity, and outcomes of AKI associated with dual renin-angiotensin system blockade. Clin J Am Soc Nephrol 11: 1944-1953, 2016
24. Tomlinson LA, Abel GA, Chaudhry AN, Tomson CR, Wilkinson IB, Roland MO, Payne RA: ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admissionswith acute kidney injury: A longitudinal ecological study. PLoS One 8: e78465, 2013
25. Montford JR, Linas S: How dangerous is hyperkalemia? J AmSoc Nephrol 28: 3155-3165, 2017
26. Snitker S, Doerfler RM, Soliman EZ, Deo R, St Peter WL, Kramlik S, Fischer MJ, Navaneethan S, Delafontaine P, Jaar BG, Ojo A, Makos GK, Slaven A, Weir MR, Zhan M, Fink JC; for CRIC Study Investigators: Association of QT-prolonging medication use in CKD with electrocardiographic manifestations [published online ahead of print August 9, 2017]. Clin J Am Soc Nephrol doi:10.2215/CJN.12991216
27. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. NEngl J Med 329: 1456-1462, 1993
28. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
29. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC: The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169: 1156-1162, 2009
30. Nakhoul GN, Huang H, Arrigain S, Jolly SE, Schold JD, Nally JV Jr, Navaneethan SD: Serum potassium, end-stage renal disease and mortality in chronic kidney disease. Am J Nephrol 41: 456-463, 2015
31. Seliger SL, Fried LF: Serum potassium in dual renin-angiotensinaldosterone system blockade. Clin JAmSoc Nephrol 9: 219-221, 2014
32. Oster JR, Singer I, Fishman LM: Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 98: 575-586, 1995
33. Kovesdy CP, Appel LJ, Grams ME, Gutekunst L, McCullough PA, Palmer BF, Pitt B, Sica DA, Townsend RR: Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension. J Am Soc Hypertens 11: 783-800, 2017
34. Sterns RH, Grieff M, Bernstein PL: Treatment of hyperkalemia: Something old, something new. Kidney Int 89: 546-554, 2016
35. Watson MA, Baker TP, Nguyen A, Sebastianelli ME, Stewart HL, Oliver DK, Abbott KC, Yuan CM: Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: A retrospective cohort study. Am J Kidney Dis 60: 409-416, 2012
36. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; OPAL-HK Investigators: Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372: 211-221, 2015
37. Garimella PS, Jaber BL: Patiromer for hyperkalemia in diabetic CKD:Anewkid on the block.AmJ Kidney Dis 67: 545-547, 2016
38. Kim DM, Chung JH, Yoon SH, Kim HL: Effect of fludrocortisone acetate on reducing serum potassium levels in patients with endstage renal disease undergoing haemodialysis. Nephrol Dial Transplant 22: 3273-3276, 2007
39. Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, Szczech L: KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia inCKD.AmJKidneyDis 62: 849-859, 2013
40. Kidney Disease: Improving Global Outcomes: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2: 279-335, 2012
41. Locatelli F, Nissenson AR, Barrett BJ, Walker RG, Wheeler DC, Eckardt KU, LameireNH, Eknoyan G: Clinical practice guidelines for anemia in chronic kidney disease: Problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 74: 1237-1240, 2008
42. Kovesdy CP, Kalantar-Zadeh K: Iron therapy in chronic kidney disease: Current controversies. J Ren Care 35[Suppl 2]: 14-24, 2009
43. Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD; FIND-CKD Study Investigators: FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 29: 2075-2084, 2014
44. Macdougall IC: Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: Oral or intravenous? Curr Med Res Opin 26: 473-482, 2010
45. Hayat A: Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res 6: 93-102, 2008
46. Remuzzi G, Ingelfinger JR: Correction of anemia-payoffs and problems. N Engl J Med 355: 2144-2146, 2006
47. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
48. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl JMed 361: 2019-2032, 2009
49. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
50. Goldsmith D, Covic A: Time to Reconsider Evidence for Anaemia Treatment (TREAT) 5 Essential Safety Arguments (ESA). Nephrol Dial Transplant 25: 1734-1737, 2010
51. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF: Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: A network meta-analysis. Cochrane Database Syst Rev (12): CD010590, 2014
52. Williams AW, Dwyer AC, Eddy AA, Fink JC, Jaber BL, Linas SL, Michael B, O’Hare AM, Schaefer HM, Shaffer RN, Trachtman H, Weiner DE, Falk AR; American Society of Nephrology Quality, and Patient Safety Task Force: Critical and honest conversations: The evidence behind the “Choosing Wisely” campaign recommendationsbytheAmerican SocietyofNephrology. Clin JAmSoc Nephrol 7: 1664-1672, 2012
53. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G; Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953, 2006
54. Chartsrisak K, Vipattawat K, Assanatham M, Nongnuch A, Ingsathit A, Domrongkitchaiporn S, Sumethkul V, Distha-Banchong S:Mineralmetabolismandoutcomes in chronic kidney disease stage 2-4 patients. BMC Nephrol 14: 14, 2013
55. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKDMBD). Kidney Int Suppl 7: 1-59, 2017
56. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM: Effects of phosphate binders in moderate CKD. J AmSoc Nephrol 23: 1407-1415, 2012
57. Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust MH, Shroff R, Thadhani RI, Tonelli MA, Kasiske BL, Wheeler DC, Leonard MB: Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: A commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 87: 502-528, 2015
58. Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, Peacock M: Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 83: 959-966, 2013
59. Hill Gallant KM, Spiegel DM: Calciumbalance in chronic kidney disease. Curr Osteoporos Rep 15: 214-221, 2017
60. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, Lok CE, Fitchett D, Tsuyuki RT: Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: An updated systematic review and meta-analysis. Lancet 382: 1268-1277, 2013
61. Collister D, Rigatto C, Tangri N: Anemia management in chronic kidney disease and dialysis: A narrative review. Curr Opin Nephrol Hypertens 26: 214-218, 2017
62. Toussaint ND, Damasiewicz MJ:Dothe benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms? Nephrology (Carlton) 22 [Suppl 2]: 51-56, 2017
63. Brancaccio D, Bommer J, Coyne D: Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: Understanding the differences among therapies.Drugs 67: 1981-1998, 2007
64. Bailey RA, Wang Y, Zhu V, Rupnow MF: Chronic kidney disease in US adults with type 2 diabetes: An updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes 7: 415, 2014
65. American Diabetes Association: Standards of medical care in diabetes-2017: Summary of revisions. Diabetes Care 40[Suppl 1]: S4-S5, 2017
66. Lipska KJ, Bailey CJ, Inzucchi SE: Use of metformin inthe settingof mild-to-moderate renal insufficiency. Diabetes Care 34: 1431-1437, 2011
67. Food and Drug Administration: FDA Drug Safety Communication: FDA Revises Warnings Regarding Use of the Diabetes Medicine Metformin in Certain Patients with Reduced Kidney Function, 2017. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed November 29, 2017
68. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME: Diabetic kidney disease: A report from an ADA Consensus Conference. Diabetes Care 37: 2864-2883, 2014
69. Abe M, Okada K: DPP-4 inhibitors in diabetic patients with chronickidneydisease andend-stage kidney diseaseondialysis in clinical practice. Contrib Nephrol 185: 98-115, 2015
70. Scheen AJ: Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet 54: 1-21, 2015
71. Prasad-Reddy L, Isaacs D: A clinical review of GLP-1 receptor agonists: Efficacy and safety in diabetes and beyond. Drugs Context 4: 212283, 2015
72. Davies MJ, Bain SC, Atkin SL, Rossing P, Scott D, Shamkhalova MS, Bosch-Traberg H, Syrén A, Umpierrez GE: Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trial. Diabetes Care 39: 222-230, 2016
73. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators: Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377: 839-848, 2017
74. Andrianesis V, Glykofridi S, Doupis J: The renal effects of SGLT2 inhibitors andamini-reviewof the literature. Ther Adv Endocrinol Metab 7: 212-228, 2016
75. Hahr AJ, Molitch ME: Management of diabetes mellitus in patients with chronic kidney disease. Clin Diabetes Endocrinol 1: 2, 2015
76. Lutz J, Jurk K, Schinzel H: Direct oral anticoagulants in patients with chronic kidney disease: Patient selection and special considerations. Int J Nephrol Renovasc Dis 10: 135-143, 2017
77. KDIGO CKD Work Group: Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation andmanagement of chronic kidney disease. Kidney Int: 1-150, 2013
78. Gabardi S, Munz K, Ulbricht C: A review of dietary Suppl 3supplementinduced renal dysfunction. Clin J Am Soc Nephrol 2: 757-765, 2007
79. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, Gnjidic D, Del Mar CB, Roughead EE, Page A, Jansen J, Martin JH: Reducing inappropriate polypharmacy: The process of deprescribing. JAMA Intern Med 175: 827-834, 2015
80. Pai AB, Boyd A, Depczynski J, Chavez IM, Khan N, Manley H: Reduced druguse andhospitalization rates inpatients undergoing hemodialysis who received pharmaceutical care: A 2-year, randomized, controlled study. Pharmacotherapy 29: 1433-1440, 2009
81. McIntyre C, McQuillan R, Bell C, Battistella M: Targeted deprescribing in an outpatient hemodialysis unit: A quality improvement study to decrease polypharmacy. Am J Kidney Dis 70: 611-618, 2017
82. Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM: Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis.AmJ Epidemiol 164: 881-889, 2006
83. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME: Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 176: 238-246, 2016
84. Pai AB, Cardone KE, Manley HJ, St Peter WL, Shaffer R, Somers M, Mehrotra R; Dialysis Advisory Group of American Society of Nephrology: Medication reconciliation and therapy management in dialysis-dependent patients: Need for a systematic approach. Clin J Am Soc Nephrol 8: 1988-1999, 2013
85. St Peter WL, Wazny LD, Patel UD: New models of chronic kidney disease care including pharmacists: Improving medication reconciliation and medication management. Curr Opin Nephrol Hypertens 22: 656-662, 2013